Feb 04, 2020
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors
Feb 04, 2020
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors
Dec 17, 2019
Scientists Find a Way to Improve the Efficiency of Chemotherapy
Nov 29, 2019
Global Doxorubicin Market Analysis and Forecast 2019-2024 - Key Players are Cadila Pharmaceuticals, Cipla, Pfizer, Johnson & Johnson
Jul 02, 2019
Monopar Therapeutics and the Spanish Sarcoma Group (GEIS) Team Up on Phase 2 Sarcoma Trial With Monopar's Novel Camsirubicin
Apr 25, 2019
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market
Jan 18, 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®
Nov 08, 2018
CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Sep 06, 2018
PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference
Aug 06, 2018
Immix Observes Complete Response in Late-Stage Canine Cancer Patient and Doses First Two Patients in Human Phase 1b/2a Study
Jun 21, 2018
CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology
Jun 07, 2018
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting
May 17, 2018
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting
Jan 17, 2018
CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer
Nov 14, 2017
Monopar Therapeutics, Inc. Announces Acquisition of GPX-150, a Broad Spectrum Phase II Cancer Drug Candidate, Closing on $9.7M in Financing, and Filing of Form 10 Registration Statement
Oct 18, 2017
Final Data on Phase I/II in Small-cell Lung Cancer with Zepsyre® Presented at the IASCLC 18th World Conference on Lung Cancer in Japan
Oct 10, 2017
PharmaMar Will Present Final Data on PM1183 During the 18th World Lung Conference in Japan
Sep 12, 2017
New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer
Jul 28, 2017
CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic
Jun 14, 2017
BioPact's MGMR® Drug Delivery Technology Succeeds In Mitigating Side Effects Of Doxorubicin While Retaining Anti-Cancer Efficacy In Lymphoma And Metastasis Mouse Models